ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1018

Methodology Of Determining An Appropriate Look-Back Period To Identify Autoimmune Rheumatic Disease In a Study Of Post-Myocardial Infarction Mortality

Mark Tacey, Megan Bohensky and Sharon Van Doornum, Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: administrative databases, Cardiovascular disease and rheumatic disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Hospital administrative datasets offer an opportunity to study the relatively rare occurrence of auto-immune rheumatic diseases (AIRD). Under-coding is a known limitation however. “Look-back” periods can be used to compensate for under-coding within the (“index”) admission of interest by identifying AIRD codes in preceding admissions for each patient. However if the timespan of the dataset is fixed, increasing the look-back period to identify more AIRD patients reduces the duration of the primary analysis period (Figure 1).  This study aimed to examine the effect of different look-back periods for identifying AIRD patients in an evaluation of the relationship between AIRD status and mortality following myocardial infarction (MI).

Methods: This study utilises a population-based hospital admission dataset with data available from 1 July 1998 to 30 June 2007. MI and AIRD status were identified using relevant International Classification of Diseases (ICD) codes. Six scenarios were defined for ascertainment of AIRD status (A to F: Figure 1), ranging from no look-back to a 5 year look-back period. Thirty-day and 1-year mortality rates were calculated from the date of the index MI. A logistic regression model was fitted with mortality as the outcome, AIRD status as the exposure and adjustment for relevant covariates. We compared the relationship between AIRD status and post-MI mortality for each scenario.

Results: As the duration of the look-back period increased (progressing from scenario A to F), the prevalence of AIRD increased from 0.7% (n=632 of 86,841 patients: scenario A) to 2.2% (n=998 of 45,447 patients: scenario F). The number of patients identified with MI decreased from scenario A to F due to the progressive reduction in the duration of the primary analysis period. Adjusted odds ratios for all-cause mortality for the AIRD group are shown in Figure 2. When no look-back period was used, no significant relationship between AIRD and 30-day mortality was identified (OR = 1.13, 95%CI 0.90-1.42). As the look-back period increased, a statistically significant relationship was obtained with an increase in the odds ratio, before stabilising with a look-back period of 3 years or longer in duration.

Conclusion: Using a look-back period to identify AIRD status changed the significance of our findings. Based on the dataset in question, there is no advantage of extending the look-back period beyond a duration of three years, with an analysis period of six years.

Figure 1 –Index MI ascertainment and look-back period scenarios


Figure 2 –Adjusted Odds Ratio for 30-day and 12-month mortality for AIRD patients


Disclosure:

M. Tacey,
None;

M. Bohensky,
None;

S. Van Doornum,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methodology-of-determining-an-appropriate-look-back-period-to-identify-autoimmune-rheumatic-disease-in-a-study-of-post-myocardial-infarction-mortality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology